Zydus' Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA received final approval from the USFDA to market Oseltamivir Powder for Oral Suspension, 6 mg/ml which is used in the treatment and prevention of influenza.

It will be produced at the Nesher Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA. The sales of Oseltamivir Powder for Oral Suspension are estimated at USD 367.92 million.

The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 3.75, or 0.78%, to trade at Rs 484.95. The total volume of shares traded was 18,162 at the BSE (9.52 a.m., Monday).